Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neuroendocrine Carcinoma (NEC)”

39 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 39 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT03647163
What this trial is testing

Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors

Who this might be right for
Solid TumorNon Small Cell Lung CancerNeuroendocrine Carcinoma+1 more
Vyriad, Inc. 33
Large-scale testing (Phase 3)Looking for participantsNCT05058651
What this trial is testing

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Who this might be right for
Advanced Extrapulmonary Neuroendocrine CarcinomaMetastatic Extrapulmonary Neuroendocrine CarcinomaRecurrent Extrapulmonary Neuroendocrine Carcinoma+1 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Looking for participantsNCT07038096
What this trial is testing

ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

Who this might be right for
Small Cell Lung CancerNeuroendocrine Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 350
Early research (Phase 1)Active Not RecruitingNCT04514497
What this trial is testing

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

Who this might be right for
Metastatic Lung Small Cell CarcinomaMetastatic Malignant Solid NeoplasmMetastatic Neuroendocrine Carcinoma+9 more
National Cancer Institute (NCI) 28
Testing effectiveness (Phase 2)UnknownNCT05142865
What this trial is testing

Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas

Who this might be right for
Advanced or Metastatic EP-NEC
Huazhong University of Science and Technology 30
Testing effectiveness (Phase 2)Study completedNCT03352934
What this trial is testing

Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy

Who this might be right for
Cancer
Johannes Gutenberg University Mainz 60
Not applicableUnknownNCT04720391
What this trial is testing

Bone Metastases in neurOendocrine NEoplasms: naTural History, Prognostic Impact and Therapeutic Approach (MONET)

Who this might be right for
Bone MetastasesNeuroendocrine Neoplasm
European Institute of Oncology 500
Early research (Phase 1)Looking for participantsNCT07006727
What this trial is testing

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

Who this might be right for
Small Cell Lung CarcinomaLarge Cell Neuroendocrine Carcinoma of the LungNeuroendocrine Prostate Cancer+1 more
Novartis Pharmaceuticals 116
Testing effectiveness (Phase 2)Looking for participantsNCT06157827
What this trial is testing

A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma

Who this might be right for
Advanced Neuroendocrine Carcinoma
Nanjing Leads Biolabs Co.,Ltd 178
Testing effectiveness (Phase 2)Study completedNCT02955069
What this trial is testing

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Who this might be right for
Well-differentiated Non-functional NET of Thoracic OriginWell-differentiated Non-functional NET of Gastrointestinal OriginWell-differentiated Non-functional NET of Pancreatic Origin+1 more
Novartis Pharmaceuticals
Early research (Phase 1)Looking for participantsNCT06889493
What this trial is testing

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

Who this might be right for
Neuroendocrine CarcinomaNeuroendocrine Tumors
Peter Hosein, MD 36
Testing effectiveness (Phase 2)Study completedNCT03136055
What this trial is testing

Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas

Who this might be right for
High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
University of California, San Francisco 36
Testing effectiveness (Phase 2)Active Not RecruitingNCT04701307
What this trial is testing

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

Who this might be right for
Lung Small Cell CarcinomaNeuroendocrine CarcinomaStage III Lung Cancer AJCC v8+3 more
M.D. Anderson Cancer Center 48
Not applicableLooking for participantsNCT06400654
What this trial is testing

PrognostIc and Predictive Factors in Unresectable Locally Advanced NEC and MANEC

Who this might be right for
Neuroendocrine Carcinoma
European Institute of Oncology 100
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07156019
What this trial is testing

Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine Carcinoma

Who this might be right for
Neuroendocrine Carcinomas (NEC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 32
Testing effectiveness (Phase 2)UnknownNCT04525638
What this trial is testing

A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours

Who this might be right for
Neuroendocrine Tumours (NET)Neuroendocrine Carcinomas (NEC)
Fundación de investigación HM 30
Early research (Phase 1)Looking for participantsNCT06132113
What this trial is testing

DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Who this might be right for
Neuroendocrine Neoplasms
Boehringer Ingelheim 55
Post-approval studies (Phase 4)Study completedNCT01317615
What this trial is testing

RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation

Who this might be right for
Carcinoma, Large CellNeuroendocrine Tumors
Novartis Pharmaceuticals 49
Testing effectiveness (Phase 2)Study completedNCT03147404
What this trial is testing

Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes

Who this might be right for
Neuroendocrine Carcinoma, Grade 3
Samsung Medical Center 14
Testing effectiveness (Phase 2)Looking for participantsNCT07174583
What this trial is testing

IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

Who this might be right for
Small-cell Lung CancerNeuroendocrine CarcinomasSolid Tumor Show to Express DLL3
IDEAYA Biosciences 208
Load More Results
189
116